Advisory Panel Votes 12-0 In Favor Of Thoratec’s HeartMate II LVAD
This article was originally published in The Gray Sheet
Executive Summary
FDA's Circulatory System Devices panel unanimously endorsed Thoratec's PMA for its HeartMate II implantable left ventricular assist device at its Nov. 30 meeting in Gaithersburg, Md
You may also be interested in...
With Approval Of HeartMate II, Thoratec Aims To Double U.S. Implant Centers
Thoratec expects to double the number of U.S. centers implanting the HeartMate II continuous flowventricular assist device from 40 to 80 by the end of 2008
With Approval Of HeartMate II, Thoratec Aims To Double U.S. Implant Centers
Thoratec expects to double the number of U.S. centers implanting the HeartMate II continuous flowventricular assist device from 40 to 80 by the end of 2008
Abiomed Invests In Long-Term LVAD Support With WorldHeart
Abiomed is diversifying its ventricular assist device holdings with a $5 million strategic investment in WorldHeart, announced Dec. 12